Portage Biotech
Portage Biotech identifies, finances, and develops best-in-class or first-in-class early-to-mid stage products, then either creates management teams to develop these assets or augments a company’s existing management teams.
The company, which is domiciled on the British Virgin Islands and has a corporate office in Canada, creates much of its value by developing pre-proof of concept assets through proof of concept, after which big pharma is often interested in acquiring or licensing them.
Portage's access to a broad network of drug development professionals helps to ensure the optimum development pathway for each compound. The company has three major portfolio companies - Portage Pharmaceuticals, Biohaven Pharmaceuticals and Sentien Biotechnologies.
Latest Portage Biotech News & Features
Today's issue
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze